Prescription medicine
Bimatoprost Brand names: Lumigan, Durysta, Zolymbus, Latisse
Bimatoprost (Lumigan) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 13 generic labelers, and pharmacies paid $6.97 per mL (Bimatoprost 0.03% eye drops) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the bimatoprost FDA label on DailyMed (effective June 22, 2024, Allergan, Inc.); the NDA 21275 record on Drugs@FDA; every bimatoprost label on DailyMed.
Highlights of the record
FDA label of June 22, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageLUMIGAN ® (bimatoprost ophthalmic solution) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Forms and strengths
- 0.1 mg/ml
- 0.1 mg/g
- 0.3 mg/ml
Solution/ drops; implant; gel.
On the market
- Earliest approval on file
- March 16, 2001 Lumigan, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 15 first December 1, 2014; 11 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 15 of which 13 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- June 13, 2027 Lumigan solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $6.97 per mL Bimatoprost 0.03% eye drops
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 5 since 2017 0 Class I among all firms' recalls; latest March 31, 2025
- FAERS reports
- 28,651 through July 30, 2026
What is bimatoprost used for?
From the label: indications and usageLUMIGAN ® (bimatoprost ophthalmic solution) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. LUMIGAN ® 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Conditions named in the indications of bimatoprost's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Prostaglandin Analog.
Source: FDA drug label (LUMIGAN), NDA022184 (Abbvie), as published by Allergan, Inc., effective June 22, 2024 (SPL set a5e67c75-db88-4372-bb07-c8dd15c97631), via openFDA; the full label on DailyMed
Is there a generic for bimatoprost (Lumigan)?
The FDA approved the first generic bimatoprost on December 1, 2014. 15 generic applications are approved; 11 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 5 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists bimatoprost from 13 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 1 patent for Lumigan solution/drops: the compound patent runs to June 13, 2027; a patent listed only for Zolymbus gel runs to June 8, 2036. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2001 earliest approval on file
- 2014 first generic approved
- 2027 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for bimatoprost (Lumigan)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $6.97 per mL (Bimatoprost 0.03% eye drops), down 45% from $12.66 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Bimatoprost 0.03% eye drops (generic)
- Lumigan 0.01% eye drops (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Bimatoprost 0.01% eye drops | Generic | $42.75 per mL | n/a | n/a |
| Bimatoprost 0.03% eye drops | Generic | $6.97 per mL | n/a | -45% |
| Bimatoprost 0.03% eyelash solution | Generic | $23.46 per mL | n/a | -8% |
| Latisse 0.03% eyelash solution | Brand | $36.23 per mL | n/a | no change |
| Lumigan 0.01% eye drops | Brand | $103.06 per mL | n/a | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has bimatoprost been recalled?
The FDA's Enforcement Report lists 5 recalls naming bimatoprost since 2017: 0 Class I (the most serious), 1 Class II, 4 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 31, 2025 | Class II | Medisca Inc. | CGMP Deviations |
| December 13, 2019 | Class III | Lupin Pharmaceuticals Inc. | Failed Impurities/Degradation Specifications: Out-of-specification result observed in any other individual impurity. |
| October 17, 2019 | Class III | Sandoz Inc | Labeling: Incorrect or missing package insert. |
| October 19, 2017 | Class III | Allergan Sales, LLC | Failed Impurities/Degradation Specifications. |
| March 16, 2017 | Class III | Allergan Sales, LLC | Failed Impurities/Degradation Specifications |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the bimatoprost label say about other medicines?
The bimatoprost label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Benzalkonium | warnings and precautions | Contact Lens Use LUMIGAN ® 0.01% contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. |
Source: FDA drug label (LUMIGAN), NDA022184 (Abbvie), as published by Allergan, Inc., effective June 22, 2024 (SPL set a5e67c75-db88-4372-bb07-c8dd15c97631), via openFDA; the full label on DailyMed
What do FAERS reports show for bimatoprost?
The FDA Adverse Event Reporting System holds 28,651 reports that list bimatoprost among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 793 are coded as a death and 3,141 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as bimatoprost?
17 other medicines are given the same way (ophthalmic) and in the same FDA class as bimatoprost or labeled mainly for the same use (glaucoma), the same class first. Glaucoma lists all 20 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Latanoprost | Glaucoma | 14 labelers | $1.58 per mL 0.005% eye drops | No current entry |
| Travoprost | Glaucoma | 11 labelers | $9.07 per mL 0.004% eye drop | A presentation being discontinued |
| Tafluprost | Glaucoma | 3 labelers | $2.45 per unit 0.0015% eye drop | No current entry |
| Latanoprost and netarsudil | Glaucoma | none listed | $139.40 per mL 0.02%-0.005% eye drp | No current entry |
| Timolol | Glaucoma | 21 labelers | $0.774 per mL 0.5% eye drops | No current entry |
| Brimonidine | Glaucoma | 12 labelers | $9.06 per mL 0.1% drop | No current entry |
| Dorzolamide and timolol | Glaucoma | 14 labelers | $0.893 per mL Dorzolamide-timolol eye drops | No current entry |
| Brimonidine and timolol | Glaucoma | 14 labelers | $2.15 per mL 0.2%-0.5% | No current entry |
Every medicine labeled for the same conditions as bimatoprost
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does bimatoprost compare with medicines for the same use?
3 side-by-side pages set bimatoprost beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to bimatoprost
- 17 medicines for the same use
- Other prostaglandin analogs
- the pharmacologic class, with prices and generics
- Bimatoprost side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other